Semnur Pharmaceuticals, Inc., formerly Denali Capital Acquisition Corp., completed a business combination with Legacy Semnur on September 22, 2025, through a merger. The company is a late-stage clinical biopharmaceutical firm focused on non-opioid pain management. Semnur's lead product candidate is SP-102, an injectable corticosteroid gel for moderate to severe lower back pain, also known as sciatica.
For the year ended December 31, 2025, Semnur reported a net loss of $160.4 million, compared to a net loss of $4.7 million for the year ended December 31, 2024. Research and development expenses totaled $2.5 million in 2025, up from $1.7 million in 2024, driven by increased personnel costs and clinical development activities related to SP-102. General and administrative expenses significantly increased to $157.9 million in 2025 from $3.0 million in 2024, primarily due to $140.0 million of consulting expense related to consultant shares issued at Closing and $9.9 million of deferred offering costs written off at Closing.
Operationally, Semnur initiated its second Phase 3 trial for SP-102 in September 2025. The company had a Type C meeting with the FDA in November 2023, where the FDA requested a confirmatory trial for SP-102. A Type D meeting followed in February 2024, providing further guidance for a 505(b)(2) NDA filing. Semnur is leveraging Scilex Holding Company's commercial infrastructure for potential commercialization, with a Transition Services Agreement in place.
As of December 31, 2025, Semnur had cash and cash equivalents of $20 thousand. The company has promissory notes totaling $3.5 million due within a year. Semnur is exploring various financing alternatives, including new credit facilities, non-dilutive financing options, debt financings and royalty financings, and equity financing options. The company anticipates commercial launch of SP-102 in 2028, subject to regulatory approval.
About Denali Capital Acquisition Corp.
A blank check company incorporated in the Cayman Islands, Denali Capital Acquisition Corp. aims to identify and complete mergers or acquisitions with businesses in technology, hospitality, or consumer services. It provides a streamlined route for target companies to go public via business combination, leveraging its industry expertise, broad network, and strategic criteria to generate value and access capital markets. The company operates as a shell entity until executing its initial business combination.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.